List of Antibodies Companies with Phase 3 Active Clinical Trial - 135

4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations. We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: - Dare to Cure - Break Boundaries - Beyond Yourself - Prepare & Execute Relentlessly Join us in creating the future of genetic medicine.

Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

We are a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, we have built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. We have assembled a world-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation. We are committed to becoming an innovative biopharmaceutical company with global vision and strives to benefit patients worldwide. Our ultimate goal is to transform cancer into manageable conditions.

Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGFS TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medical needs. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode. Akeso is actively developing a diverse pipeline of over 50 innovative assets in cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, and 13 pivotal/phase III trials ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The Company’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the Company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Our mission is to improve patient lives and the sustainability of the global healthcare ecosystem by broadening the availability and accessibility of biosimilars.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.

Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team’s experience and scientific expertise in new drug development, Angitia is dedicated to bringing innovative therapeutics to help patients in need.

Annexon Biosciences is a clinical-stage biopharmaceutical company developing novel therapies for autoimmune and neurodegenerative diseases, including ophthalmic diseases.

At Annovis Bio, Inc., we are pioneering a novel approach to fighting chronic and acute neurodegeneration, offering new hope against the largest unmet need of our aging population - Alzheimer’s and Parkinson’s diseases. Our diverse pipeline also targets such neurodegenerative conditions as traumatic brain injury (TBI), stroke, Down Syndrome, Huntington disease, and mental illnesses. Our lead compound, buntanetap, is a small, once-daily, orally administered, brain-penetrant inhibitor of neurotoxic proteins. The biological activity of buntanetap has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University, and Harvard University. We have also conducted seven clinical studies in over 1,000 people, which consistently showed that buntanetap is safe and well-tolerated. Moreover, buntanetap has shown the ability to normalize levels of several neurotoxic proteins – APP, tau, aSYN – to those seen in healthy volunteers. In our late-stage trials, buntanetap significantly improved cognitive functions (ADAS-Cog11) in patients with mild Alzheimer’s disease, halted cognitive decline in Parkinson’s patients, and improved motor and non-motor Parkinson’s-related functions (MDS-UPDRS) in several disease subpopulations. We are currently in the process of submitting our latest data to the FDA and planning two pivotal Phase 3 studies—one for Alzheimer’s and one for Parkinson’s. We believe that buntanetap holds the potential to be the first drug to address the underlying mechanisms of neurodegeneration, heralding a new era in the treatment of these debilitating diseases.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of Treating Patients Beyond Borders. Since 2017, Antengene has built a pipeline of 9 oncology programs at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. We have successfully obtained marketing authorizations for selinexor, Antengene’s lead asset, in multiple Asia Pacific counties and regions including mainland China, Taiwan,China, South Korea, Singapore, and Australia.

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019.

Aptitude Vision is a biotechnology company that specializes in developing next-generation synthetic biomolecules for treating vision-threatening diseases by simultaneously targeting multiple pathological processes.

Arcus Biosciences is an exciting growth company founded on the vision of creating best-in-class cancer therapies. We are an oncology-focused biopharmaceutical company leveraging its deep cross-discipline expertise to discover highly differentiated therapies and develop a broad portfolio of novel combinations addressing significant unmet needs. We are located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub. Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus is an ambitious undertaking, and we fully expect our company to become a force in the discovery, development and commercialization of novel therapies for the treatment of cancer. Our employees enjoy operating in an exceptionally dynamic and cooperative environment in which the “rule book” has not yet been written.

ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.

Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.

āshibio is developing novel therapies for patients with rare bone and connective tissue disorders that have the potential to prevent the onset of symptoms or slow the progression of disease.

At Astria Therapeutics, our team is focused on bringing therapies with the potential to improve the quality of life to patients and families affected by Hereditary Angioedema (HAE) and rare allergic and immunological diseases. Our name originates from the Greek word for star, and patients are guiding stars who guide us in the development of life-changing therapies. Learn more at www.astriatx.com

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company’s lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases.

四川百利天恒药业股份有限公司 百利药业是一家集研发、生产、营销为一体的现代化高新技术企业。拥有2个新药研发中心、1个抗体及ADC药物生产企业、1个化学中间体生产企业及1个化学原料药生产企业、2个化学。

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. On November 14, 2024, the company announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.

BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. The Company is developing treatments in two of the world’s largest markets, China and the United States. BeyondSpring’s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent, is being developed as a “pipeline in a drug” with potential to be an anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). In the DUBLIN-3 Phase 3 study, the plinabulin and docetaxel combination met the primary endpoint of extending overall survival, compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (EGFR wild type). In addition, the plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data, for which it received Breakthrough status in the U.S. and China. Plinabulin is also currently being studied as part of other immuno-oncology (IO) combination regimens that include radiation and/or checkpoint inhibitors for the treatment of a number of cancers. Lastly, BeyondSpring also has three preclinical IO assets and majority ownership in its subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

BIOCAD is Russia's leading innovative biotechnology company; it combines a world-class research and development center, ultra-modern pharmaceutical and biotechnological manufacturing facilities, as well as preclinical and clinical research infrastructure compliant with international standards. BIOCAD is one of the world`s few full-cycle drug development and manufacturing companies, from new molecule discovery and genetic engineering to large-scale commercial production and marketing support. BIOCAD`s medicines are dedicated to treat complex health conditions such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.

BioCity was established in December 2017. It is an innovative drug company created by local entrepreneurs who have a deep understanding of the Chinese pharmaceutical market and young returned scientists relying on the world's leading open drug innovation platform. The company is committed to the discovery, development and commercialization of novel or highly differentiated candidates (with no modality limitation) to treat diseases with significant unmet medical needs, particularly cancers and Nephropathy. Through internal research, open innovation platform and collaborations, BioCity has established a pipeline of more than 10 innovative programs including small molecules, monoclonal and bispecific antibodies as well as antibody-drug conjugate (ADCs).

Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

Biologics Resources, LLC (BRLLC) is a Vaccines, immunotherapeutics and Biopharmaceuticals technology company.

BioNTech is a global next generation immunotherapy company aspiring to translate science into survival. Around 6.100 pioneers currently work with us, employing a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules.   Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. To learn more about us, please visit www.BioNTech.com. Our privacy statement can be found here:  https://www.biontech.com/int/en/home/data-privacy-statement.html Our imprint can be found: https://www.biontech.com/int/en/home/imprint.html

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark, and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. To learn more about our products and their availability in your country, please visit https://bioporto.com/products/. Posts are not intended for a U.S. audience. If you are from the United States, you are encouraged to visit https://www.linkedin.com/company/bioporto-diagnostics-inc-us/ Social Media Community Guidelines: https://bioporto.com/social-media/

Biotest is a specialist supplier of plasma proteins and biotherapeutic drugs used to treat diseases of the immune system or the haematopoietic system. The value chain of the medium-sized company, which was founded in 1946 as a family business, ranges from pre-clinical and clinical development to worldwide marketing. Biotest specialises primarily in the fields of clinical immunology, haematology as well as intensive care and emergency medicine. As the world market leader in hyperimmunoglobulins and the only manufacturer of IgM-enriched immunoglobulins, Biotest sees itself as an expert for innovative products for the prevention and therapy of life-threatening and rare infections. In addition, Biotest supports doctors and patients with coagulation factors that are also produced on the basis of human blood plasma. Among other things, the company has state-of-the-art plasmatic factor VIII and factor IX concentrates for the treatment of the congenital coagulation disorders haemophilia A and haemophilia B. Since 2019, the product portfolio also includes a first recombinant FVIII preparation from a human cell line. Biotest currently employs more than 2,000 people worldwide, the majority of whom are based at the company's headquarters in Dreieich near Frankfurt. The internationally active specialist supplier has subsidiaries in eight countries and sells its products in more than 80 countries. The plasma used is mainly obtained in the company's 22 plasma collection centres in Europe and meets the strictest official safety and quality requirements. Biotest manufactures all products exclusively in Germany.

Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HBV infection. Bluejay has exclusively licensed global rights to advance several HBV programs, including a best-in-class anti-HBsAg monoclonal antibody.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer. BriaCell achieved positive proof-of-concept in a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT™ in combination with a PD-1 inhibitor, retifanlimab (provided by Incyte under a collaboration agreement). Additionally, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for advanced breast cancer.

CanariaBio is a biopharmaceutical company that focuses on developing and commercializing immunotherapies for cancer, utilizing a technology platform of tumor antigen specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu.

Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody-drug conjugates, immune system modulators and other protein-based therapeutics that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications.

CG Oncology, Inc. (Nasdaq: CGON), is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative oncolytic immunotherapies to live with dignity and have an enhanced quality of life. Our lead candidate, cretostimogene grenadenorepvec, is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA® (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene grenadenorepvec in combination with OPDIVO® (nivolumab).

About Chembio Diagnostics: Chembio is a leading point-of-care diagnostics company focused on creating fast actionable tests to diagnose diseases quickly and accurately, including STIs and COVID-19, enabling expedited treatment. Chembio tests are easy to use and provide results in approximately 15 minutes using some of the smallest sample sizes of fingertip blood, nasal swabs and other sample types. Chembio recently received FDA CLIA Waiver for the first rapid point-of-care combination test for HIV & Syphilis. Coupled with Chembio's extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com. About the DPP Rapid Test Platform: Chembio's proprietary DPP® technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio's easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

Chugai’s strength in R&D and antibody technologies continues on in global efforts for products and services for the benefit of patients. Chugai Pharma USA, Inc. (CPUSA), located in Berkeley Heights, NJ, is a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai). CPUSA supports the planning and execution of global and U.S. clinical programs for Chugai-originated, innovative new drug candidates. Chugai is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs in Chugai’s strategic fields of oncology, bone and joint diseases, and renal diseases as well as other therapeutic areas with serious unmet needs. Chugai develops its products independently from Roche until early Proof-of-Concept (PoC) for worldwide market, including U.S. For late stage clinical development and marketing outside of Japan, South Korea, and Taiwan, Chugai seeks for partnership with Roche, which has the first refusal rights to develop/sell Chugai products, or other third parties.

CinnaGen is an Iranian biotechnology company founded in 1994 and headquartered in Tehran. It is recognized as a leading biopharmaceutical manufacturer and exporter in the Middle East and North Africa (MENA) region. The company adheres to modern quality standards and complies with Good Manufacturing Practice (GMP) regulations for food and pharmaceutical products. CinnaGen offers contract development and manufacturing services, supporting the development of biopharmaceutical products. The company specializes in biosimilars, particularly for immunological diseases, infertility, hormone disorders, and oncology. Notable products include Cinnovex, a biosimilar for multiple sclerosis, as well as therapeutic recombinant proteins, molecular diagnostic kits, and synthetic peptides. CinnaGen's products are exported to various countries, aiming to enhance patient outcomes in the healthcare sector. The company has achieved significant milestones, including being the first in the MENA region to manufacture Taq DNA polymerase and monoclonal antibodies, and it has received GMP certification from the European Medicines Agency for its biologic plant.

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Convalife Pharmaceuticals is an innovative pharmaceutical company that specializes in drug research and development for tumor diseases. They are dedicated to developing innovative drugs and focus on antibody biopharmaceuticals and small molecule treatments.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial.

CStone (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received ten NDA approvals for four drugs. Multiple late-stage drug candidates are now under pivotal clinical trials or registration. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.

Receiving blood is receiving life. DIAGAST's goal is to help healthcare professionals transmit life with the help of the best blood group determination technologies. Even though it is not always a matter of life and death, transfusion errors are never acceptable. Over the last 30 years, DIAGAST has developed unparalleled expertise and know-how in the transfusion sector. DIAGAST develops, manufactures and markets reagents (for blood group determination), miniaturized laboratories for manual analysis and automated systems. DIAGAST also ensures the research, manufacturing and marketing of all its products. Moreover, DIAGAST offers a wide range of related services, such as a training center for their automated systems, a hotline and on-site follow-up on automaton calibration. We even make control and measurement tools available over the Internet. DIAGAST is now the worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions.

Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.

About DualityBio DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next generation Antibody-Drug Conjugate (ADC) technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced 4 assets into global clinical studies, and developed more than 10 innovative product candidates which are currently in preclinical stage. Additionally, DualityBio is continuing evolving its novel protein engineering and ADC technology platforms for the next wave of “super ADC” molecules including diverse payload classes, bispecific ADCs and dual payload ADCs. For more information, please visit www.dualitybiologics.com. 关于映恩生物 映恩生物（Duality Biologics）是一家临床阶段的创新生物药企，专注于为全球癌症患者和自身免疫性疾病患者研发新一代 ADC 疗法。映恩生物已成功构建了多个具有全球知识产权的新一代抗体偶联药物（ADC）技术平台。基于对疾病生物学机制的深入研究和探索，映恩生物已经拥有四项临床管线与十多项临床前创新项目并持续改进其新型蛋白工程和ADC技术平台，以开发下一代“超级ADC”分子，包括全新作用机制载荷、双特异性ADC和双有效载荷ADC。映恩生物已与海内外多个跨国药企达成多项重磅授权合作，并在全球开展多个国际多中心（MRCT）关键性临床研究。致力于成为世界领先的ADC公司。 如需更多信息，请访问www.dualitybiologics.com

Electra Therapeutics is a clinical stage biotechnology company developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer.

Sinovent is a global biopharmaceutical company focused on discovery, development, and commercialization of innovative therapeutics for the treatment of cancer and autoimmune diseases.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.

On June 6, 2024, AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. It also strengthens AstraZeneca’s presence in and commitment to Canada. As a result of the acquisition, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US. At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer. We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.

Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.

Founded in 2007, Genor Biopharma Co. Ltd (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's top oncology areas (breast, lung, and gastrointestinal cancer).

Hansa Biopharma, is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative and life altering treatments for patients with rare immunological conditions. Hansa scientists are working on developing immunomodulatory treatments for organ transplants, rare IgG-mediated autoimmune conditions, and gene therapy, as well as exploring the potential application of the technology platform in oncology.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

ImmunityBio (previously NantKwest (NASDAQ: NK)) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells. ImmunityBio is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. Our “off-the-shelf” activated Natural Killer (NK) platform have the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease. Our targeted therapeutic areas include: (1) cancer, focusing on bulky hematological cancers and solid tumors as well as cancer stem cells, (2) infectious diseases, including viral, fungal and bacterial infections, and (3) inflammatory diseases, ranging from rare inherited diseases to more prevalent autoimmune disorders.

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company’s lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunome Inc., a biotechnology company, discovers, develops, and commercializes highly targeted and native human cancer antibodies against universal cancer antigens. Its RealMAb technology enables the discovery of novel antigens and the cognate native human antibodies that target antigens; and ScreenMab multiplex functional screening technology identifies monoclonal antibodies that have exquisite for tumor neoantigens. The company was founded in 2006 and is based in Exton, Pennsylvania.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.

Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”. The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden. The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world’s largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com

Inhibrx is a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence. They have a pipeline of novel biologic therapeutic candidates developed using their protein engineering expertise.

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Pioneers in the biology of Natural Killer cell, Innate Pharma has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

InnoCare Pharma is a commercial stage biopharmaceutical company dedicated to discovering, developing, and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. InnoCare has strong in-house innovation capabilities, holding multiple foreign and domestic patents with a rich product pipeline target liquid tumors, solid tumors, and autoimmune diseases. Our team has discovered and developed a strong pipeline. InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding leader in the biopharmaceutical industry. We have over 1000 employees. Our core R&D staff brings rich experience from the world's top pharmaceutical companies, such as Pfizer, GSK, Bristol-Myers Squibb, Merck, Johnson & Johnson, Bayer, etc. We are a truly global biopharmaceutical company with sites in Beijing, Nanjing, Shanghai, and Guangzhou, Hong Kong and Unites States. On March 23, 2020, InnoCare officially listed on the Hong Kong Stock Exchange (code: 9969). And on Sept. 21, 2023, InnoCare successfully got listed on STAR Board of Shanghai Stock Exchange (code: 688428). Our vision is to become a world-class biopharma leader to address the unmet medical needs globally.

We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these metabolites. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.

ISU ABXIS is continuously striving to provide better treatment options for patients suffering from difficult-to-treat diseases based on Isu’s excellence in biotechnology.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

JCR Pharmaceutical is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. Our core values – reliability, confidence, and belief – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We continue to build upon our 49-year legacy in Japan while expanding our global footprint with trials in the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. We are leaders in developing therapies for rare conditions, including lysosomal storage disorders (LSDs). We are building on the development work we've done in Japan to expand our LSD pipeline: Our first-in-class proprietary technology, J-Brain Cargo®, enables us to develop therapies that cross the blood-brain barrier and penetrate the central nervous system (CNS). The CNS complications of diseases are often severe, resulting in developmental delays, an impact on cognition and, above all, poor prognosis, which affect patients' independence as well as the quality of life of patients and their caregivers. With J-Brain Cargo®, we seek to address the unresolved clinical challenges of LSDs and CNS-related disorders, including neurodegeneration, neuro-oncology, and neuro-inflammation conditions, by delivering the therapy to both the body and the brain. We will continuously try to create value by our unique J-Brain Cargo® technology platform toward our corporate philosophy: “contributing towards people’s healthcare through pharmaceutical products.” In addition to the in-house research activities, we think collaborative research and development work with other companies are also important. The value of our technology platform will be increased by integrating ours with other technologies and by implementing J-Brain Cargo® within other companies’ products.

科兴制药是一家主要从事重组蛋白药物和微生态制剂的研发、生产、销售一体化的创新型生物制药企业，专注于抗病毒、血液、肿瘤与免疫、退行性疾病等治疗领域的药物研发，并围绕上述治疗领域拥有一定中药及化学药技术沉淀。 科兴制药主要产品包括重组蛋白药物"重组人促红素"、"重组人干扰素α1b"、"重组人粒细胞刺激因子"，微生态制剂药物"酪酸梭菌二联活菌"。公司主要产品已沉淀一定行业优势地位和市场影响力，近年来依托政策支持和营销渠道深耕，保持稳定增长。

Kiniksa is a publicly traded biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines designed for patients suffering from debilitating immunological diseases with significant unmet medical need. We have a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. We are relentless and focused on patients and strive to develop life-changing medicines. We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company’s preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.

Founded in 2019 in Shanghai, China, LaNova Medicines is a clinical-stage biotechnology company committed to the discovery and development of novel biologic drugs for cancer treatment. Led by industry veterans with a strong passion for innovation, we aim to operate as an R&D engine and deliver transformative medicines to address the unmet clinical needs of cancer patients. Leveraging our proprietary technology platforms and deep understanding of the tumor microenvironment. we have built a differentiated pipeline of products and are striving to progress our programs toward the clinic.

Lumen Bio is a clinical-stage biotechnology company developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases.

mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.

Mabylon AG is a Swiss biotechnology company harnessing the therapeutic potential of naturally occurring human antibodies to treat allergies, neurodegenerative diseases, and inflammation. The firm’s strength is rooted in extensive and successful experiences in both the pharmaceutical and biotech industry, along with a solid academic track record.

Medilink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and the latest generation of technologies and products. Founded in 2020, the company is dedicated to developing globally competitive conjugated drugs with a focus on therapeutic effect.

Memo Therapeutics AG (“MTx”) is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company’s lead program, Potravitug, is in Phase II development targeting BK viremia (BKV) in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become the best and first-in-class BKV disease-modifying therapy for kidney transplant patients. Alongside Potravitug, MTx is focused on discovering novel antibody-target pairs for oncology based on tumor infiltrating B-cells derived leveraging tertiary lymphoid structure biology. The Company has a partnership in place with Ono Pharmaceutical for two oncology targets. Underpinning MTx’s core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.

Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused and capital efficient manner. Our journey began back in March 2015 fuelled by the desire to champion high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired three product candidates from Novartis in 2015 and one from AstraZeneca in 2017. Merging with OncoMed in 2019 strengthened our foundation, broadening our reach and adding cutting-edge oncology programs to our pipeline. The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options. Mereo’s agile approach is enabling us to move rigorously but quickly through trial programs. We have taken two therapies from in-licensing to pharma through to Phase 3 studies in under 5 years. Our portfolio covers potential therapies addressing critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and two oncology product candidates. Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across pharma and biotech. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We know what it takes to navigate reimbursement, which can be complex and have the expertise to drive excellence. Follow our updates on this extraordinary journey as we continue to collaborate with our stakeholders to forge new ways of doing things in rare disease.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.

OUR MISSION: Deliver Innovation. Empower Discovery. Improve Life. For over 25 years, Mirus Bio has pioneered the development of transfection reagents and proprietary technologies for nucleic acid delivery applications. Our work is both technical and cutting-edge, and we promote a culture of creativity, responsibility, and respect. Our team members are engaged and motivated by the desire to support our customers and partners to achieve strong results. Mirus, together with Gamma Biosciences, is establishing the future of science and medicine by developing products that enable product developers within the cell and gene therapy space. As we approach a new era of addressing and conquering life-altering diseases, we will continue to expand our expertise and leadership in transfection to be integral in the future of advanced therapies.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

Nippon Shinyaku Co., Ltd. is a company that has always devoted serious efforts to make people's lives better. All these efforts have been made based on their strong belief that they should build a healthier future. The company is involved in the manufacture and sale of pharmaceuticals and foodstuffs, and its functional food products find application in various industries such as meat processing, fish processing, dairy product, prepared food, confectionery and bakery, and beverage. Nippon Shinyaku also has research laboratories and a botanical research institute, as well as production and logistics facilities. The company is committed to ESG management and provides information to shareholders and investors through its IR activities. Nippon Shinyaku Co., Ltd. is headquartered in Japan and has branch offices and group companies in various locations.

OBI Pharma, Inc. is a Taiwan based bio-pharma company founded in 2002. Our mission is to improve health and the quality of life through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancer by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets. Our leading compound is Adagloxad simolenin, a late-stage novel active immuno-oncology (IO) Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. OBI has a full spectrum of Globo Series IO pipeline, which includes both active (vaccine) and passive (monoclonal antibody & antibody drug conjugate) therapeutics. Development of OBI-888 (Globo H monoclonal antibody), OBI-833 (Globo Series vaccine) for epithelial cancers, OBI-999 (Globo H antibody drug conjugate), OBI-898 (SSEA-4 monoclonal antibody), and OBI-866 (SSEA-4 vaccine) for multiple cancers are also underway. In addition, development of OBI-3424, a novel First-in-Class compound targeting both solid and liquid that express the Aldo Keto Reductase 1C3 enzyme, further enriches the company’s pipeline profile. OBI Pharma, Inc. is publicly listed on the Taipei Exchange (TPEx: 4174); wholly-owned subsidiaries are present in the United States and China. The company is led by management team with a track record of success in new drug development and commercialization.

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. For more information, please visit: www.oculis.com

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Based in Rockville, Maryland, OncoC4 is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment.

Oneness Biotech is dedicated to fulfilling unmet medical needs by developing new drugs focused on chronic disorders in dermatology and immunology

OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: • Tedopi® (T-cell specific immunotherapy): Company’s most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. • OSE-279 (anti-PD1) advanced preclinical stage • OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia • VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing in the US (sponsor Veloxis). • BI 765063 (anti-SIRPα mAb on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Ph 1 dose escalation results in mono and in combo, in particular with anti-PD-1 antibody ezabenlimab; BI sponsored international Ph 1b clinical trial ongoing in combo with ezabenlimab alone or with other drugs in recurrent/metastatic HNSCC and HCC. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics: • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Most advanced BiCKI® candidate is targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO & immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb), most advanced candidate generated by the platform, with the potential to resolve chronic inflammation.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.

PDS Biotech is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies based on the Versamune® platform, a T-cell activating technology, designed to harness the power of the body's immune system in the fight against cancer and infectious disease.

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in-vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the tumor neo-vasculature both in animal models and in cancer patients. At present, Philogen has four promising anti-cancer antibody derivatives and an antibody derivative for the treatment of rheumatoid arthritis in clinical studies. Two registrational studies are in planning. Our Zurich-based daughter company Philochem serving as the R&D unit isolates the most promising candidate products, while in Siena (Italy) the pharmaceuticals are produced according to GMP standards and advanced to clinical trials. Philogen generates revenue from a diversified range of activities, has signed agreements with major pharmaceutical companies and owns a diversified portfolio of international patents.

Pierre Fabre Group held by the Pierre Fabre Foundation, is a worldwide company with a unique positioning : the alliance of pharmaceutical and dermocosmetics expertise. This makes Pierre Fabre Group : 💊 A pharmaceutical group with a strong positioning : medical and natural 🥈 The second largest dermo-cosmetics laboratory in the world 🥈 The second largest private French pharmaceutical group 🥇 The market leader in France for products sold over the counter in pharmacies. Our portfolio includes several medical franchises and international brands including ; Pharmaceutical Care Pierre Fabre Oncologie Pierre Fabre Dermatologie Naturactive Eau Thermale Avène Klorane Ducray René Furterer A-Derma Pierre Fabre Oral Care Glytone (US) Darrow (Brasil) Established in the Occitanie region since its creation, we manufacture over 95% of our products in France. We keep innovating passionately with our teams in 2 innovation centers in Brasil and Japan as well as in 6 R&D centers in France. Thanks to our 9,600 employees in 44 subsidiaries and our distribution activities in 120 countries, our group generated €2.7 billion in revenues in 2022, 69% of which is from international business. Pierre Fabre Group has a unique company structure. 86% of the Pierre Fabre Group is held by the Pierre Fabre Foundation, a government-recognized public-interest foundation, while a smaller share is owned by its employees via an employee stock ownership plan. In 2020, the independent organization ECOCERT Environment awarded Pierre Fabre's CSR policy at "excellence" level : - Excellence being the highest maturity level of the ECOCERT 26000 standard.

At Promega Corporation, creativity and connection drive discovery and innovation. We celebrate scientific discovery and the creative application of science to solve problems. Interactions with our customers, partners and vendors are central to everything we do, and we value those relationships. We seek out and build connections across the globe and in our local communities because creative problem solving requires a network of diverse ideas and viewpoints. We develop and evolve technologies and instrumentation in collaboration with scientists and researchers around the globe. From simple cloning vectors used to address fundamental questions in biology to bioluminescent assays that help us monitor food safety and water quality, we work side-by-side with our partners in academic, industrial and government institutions to bring the best minds to bear on the toughest questions. Since 1978, we have done this all with a steadfast commitment to sustainable business models that protect our environment, inspire and develop our employees as individuals, support the wellbeing and growth of our communities, and strengthen our relationships with our customers. With 16 branches around the world, Promega products are used by a global community of life scientists who are asking fundamental questions about biological processes as well as by scientists who are applying scientific knowledge to diagnose and treat diseases, discover new therapeutics, and use genetics and DNA testing for human identification.

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.

Rakuten Medical, Inc. is a global biotechnology company developing and commercializing precision, cell-targeting investigational therapies on its AlluminoxTM platform, which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Outside of Japan, Alluminox therapies have not yet been approved as safe or effective by any regulatory authority. The company’s first drug developed on the Alluminox platform, ASP-1929, has received approval from the Japanese Ministry of Health, Labour, and Welfare, and is currently the subject of a global phase 3 clinical trial for recurrent head and neck cancer. Rakuten Medical is committed to its mission to conquer cancer by delivering our innovative treatments as quickly and safely as possible to as many patients all over the world as possible. The company has locations in 6 countries, including the United States, where it is headquartered, Japan, Taiwan, the Netherlands, Switzerland and India.

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.COVID-19: Renalytix has entered into a joint venture with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”), Kantaro Biosciences, LLC (“Kantaro”), to develop and scale production of COVID-19 antibody test kits.

Ridgeback Biotherapeutics is a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases. The team at Ridgeback is dedicated to working toward finding life-saving and life changing solutions for patients and diseases that need champions. Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company; all funding for Ridgeback Biotherapeutics has originated from Wayne and Wendy Holman; two science driven individuals who invest in technologies that they believe will make the world a better place.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, endocrinology, hematology and nephrology. For more information, please visit: www.samsungbioepis.com. To see our community guidelines, please visit: bit.ly/2l0yiI3

Saol Therapeutics (pronounced "Sail") is a privately held, clinical-stage, pharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda. The company is focused on development activity in CNS disorders such as pain management and spasticity and orphan diseases. Saol is committed to providing and advancing therapeutic options for patients and the physicians treating these populations and currently has two Phase 2 trials and one Phase 3 trail underway in the United States.

Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. On Dec. 14, 2023, Pfizer completed the acquisition of Seagen.

A diagnosis of a serious illness can change life in an instant and finding treatment options is key. At Secura Bio®, we see things differently. We develop and commercialize innovative medicines and life changing products for the patients that need them most.

Shanghai Henlius Biotech isabiopharmaceutical company in China that is developing biologics foroncology and autoimmune diseases.

海思科医药集团成立于2000年，是一家以新药研发为核心，销售能力特别突出的医药类集团化上市公司。集团是肠外营养行业领导者，在肝病领域细分市场占据重要地位，是全国排名前列的肝病用药生产销售基地，现有员工超过1900名。 公司自2012年1月17日在深圳证券交易所A股上市以来，在资本市场有着良好的表现，目前股票市值约270亿人民币，A股排名前380、中小板排名前59、全国医药上市公司中长期排名25、化学药子行业上市公司排名第7 位、上市公司市值管理绩效百佳榜第9位、中国上市公司市值管理绩效百佳、中国医药行业最具影响力榜单成长50强企业、2014福布斯中国上市潜力企业100强位列第三位、医药类企业第一位、2015福布斯中国潜力企业。 公司坚持以新产品研发作为企业发展的核心驱动力，经过多年积累与实践，公司已建立450人的研发团队，其中包括50余名博士、近百名硕士，95%以上成员具有药学或相关专业本科以上学历，公司研发团队技术水平、团队人数在国内医药企业处于领先水平，公司首仿成功率行业第一，近五年新药批件取得数量全国第三。 公司于2015年正式进军高端医疗器械市场。

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline.

Surgimab SAS is a biotechnology company based out of Montpellier, Languedoc-Roussillon, France.

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Synbio Technologies aims to become the most trusted provider of DNA solutions that empower scientific discoveries by providing highly-accurate and cost-effective synthetic biology services and products for researchers around the world. We have developed a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities for various applications, including diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuel implication, and more. Our scientific capabilities cover all facets of DNA synthesis and engineering, offering a full range of support for molecular biology work, including but not limited to, oligo synthesis, gene synthesis, subcloning & PCR cloning, plasmid preparation, mutagenesis, DNA variant libraries, CRISPR sgRNA, protein expression and purification in multiple systems. Relying on our strong DNA sequencing, synthesis, engineering technology platform, and expertise in bioinformatics analysis, we have developed proprietary algorithms to facilitate and expedite the antibody discovery process. Our antibody discovery services include hybridoma sequencing, immune repertoire sequencing, antibody design and production, AI-guided heavy chain and light chain pairing, antibody humanization, affinity maturation, and sdAb.

SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.

Located in Redmond WA, founded in 2014, Systimmune Inc. is a bio-pharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and tri-specific antibodies, as well as antibody-drug conjugates (ADC's). Our objective is to create biologics that work through systematic intervention on the solid tumor micro-environment, to either directly attack the tumor and/or to activate the immune system to attack the tumor. We are a group of highly experienced immuno-oncology scientists utilizing several technology platforms to develop world class advanced antibody-based drug therapies.

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Leading with purpose. Every day. “Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and diverse clinical pipelines in rare disease. Our focus is on doing the right things for patients both during development and commercialization to deliver on the promise of these therapies in a way that's meaningful for rare disease communities.” Emil D. Kakkis, M.D., Ph.D. Chief Executive Officer and President We have an inclusive culture of value and respect. Ultragenyx brings novel products to those living with rare and ultrarare diseases with a focus on debilitating genetic diseases. Founded in 2010, we have rapidly built a diverse portfolio of approved therapies and products aimed at diseases with a high unmet medical need for which many have no approved therapies. It takes courage, care, talent, and dedication to make a meaningful impact for those living with rare diseases, their families and the rare disease community. We put our people first, so they can take care of the rare disease community. We purposefully cultivate and nurture a dynamic, supportive work environment where we encourage every team member to share their new ideas and help us unlock more possibilities. Our team is made up of exceptional and diverse people with a strong passion and commitment to helping those living with rare diseases. By embracing generosity, curiosity, inclusion, and humility we are constantly learning together—fostering an environment that supports profound growth and fulfillment. If you want to have a meaningful impact, do the best work of your career while having fun and growing professionally and personally, come join our team! Visit our community guidelines at: https://ultragenyx.co/community

United BioPharma (UBP) was established in September 2013 as a spinoff company from UBI which was founded in 1985 in the USA. UBP focuses on developing, manufacturing, and marketing integrated therapeutic mAb products and related technologies. In addition, UBP also provides fully integrated and high-quality CDMO services. We commit to meeting our client's needs. Among +250 employees, 50% are in R&D and 65% have a master’s degree or higher. Global facilities of UBP include clinical development, R&D, manufacturing centers in Taiwan and China, as well as business centers in the USA and Taiwan.

Valneva is a specialty vaccine company providing prevention against diseases with major unmet medical needs. The Company has a growing commercial business with two successful vaccines for travelers. Our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today, a single-shot chikungunya vaccine candidate and an inactivated vaccine candidate against COVID-19.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Vigeo is focusing on tumors that are largely refractory to approved therapies. Our approach to drug development and treatment is based on targeting both the tumor and the genetically normal cells that comprise the microenvironment, which are less likely to develop mutation-based resistance. Therefore, we believe Vigeo’s therapies can have a significant impact on cancers where other types of therapy have been unsuccessful. Vigeo is the first, and only, company developing therapies designed to stimulate Tsp-1 expression by replicating the biological activity of prosaposin (PSAP). By triggering the production of TSP-1 and downstream activities via CD36 and CD47, we are reprogramming the tumor microenvironment from one that is immunosuppressive and tumor-promoting, to one that activates the immune system and is tumor-inhibiting.

Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and beyond. Our powerful R&D engine combines our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant global burden. Our current pipeline consists of multiple clinical candidates targeting hepatitis B and hepatitis delta viruses and human immunodeficiency virus, including a potential functional cure for chronic hepatitis B and treatment for chronic hepatitis delta. Our portfolio of broad, potent investigational monoclonal antibodies also targets influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus and human papillomavirus, and our investigational T cell vaccine aims to prevent HIV. Explore our full pipeline: https://bit.ly/3tr7FPm We collaborate with some of the world’s leaders in industry as well as government agencies and non-profit organizations enabling us to rapidly advance cutting-edge scientific discoveries and innovative technologies with the potential to benefit people around the world. We are proud to have been ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™. Join us as we pursue our mission to transform lives. It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world. The company was founded by Dr. Samantha Du, Chairperson and CEO, in 2014 to help address significant unmet medical needs in China and to be at the forefront of medical innovation.

Zenas BioPharma (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC). Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with investigational new drug applications for ZW220 and ZW251 planned for 2025.